NebraskaChase retweeted
An enormous week for Nebraska football kicks off with Matt Rhule making a cameo, and having dialogue in the season finale of Lanterns on HBO.
Just when I thought I’d seen it all.
NebraskaChase retweeted
Ian Happ put $300 on a baseball and threw it to the Wrigley bleacher creatures to grab some beers in what could be his final games as a member of the Cubs
NebraskaChase retweeted
I am grateful to the NBPA for advocating on my behalf and to the NBA for their fair decision. It was so important to me to be present for the birth of my daughter in December and I appreciate Mark, Jeanie, Rob, JJ, and the entire Lakers organization for fully supporting me and allowing me to travel to be there. This season has been so special to me because of what my teammates and I have been able to accomplish, and I am honored to have the opportunity to be considered for the league’s end-of-season awards.
NebraskaChase retweeted
Someone made a deal with the Devil. #DownTheRoad from @ChrisWebby x @Renmakesmusic is out now. 😈 inpatient.lnk.to/DownTheRoad
NebraskaChase retweeted
#DownTheRoad is only the beginning .. me and my brother @Renmakesmusic are just warming up ..
#Inpatient is officially here and ready to welcome yall to the #Asylum .. buckle up 😈🕸
LINK : inpatient.lnk.to/DownTheRoad
NebraskaChase retweeted
For anybody left in the state of Nebraska...
where we watching from tonight Husker Nation!?
NebraskaChase retweeted
$IBRX Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation.
Single apheresis yields up to 5 billion (5×109) highly pure activated memory cytokine-enhanced NK cells (M-ceNK), providing up to 8-10 doses of M-ceNK product per patient
businesswire.com/news/home/2…
NebraskaChase retweeted
We’ve announced a milestone in large-scale production and cryopreservation of memory cytokine-enhanced natural killer (NK) cells from more than 60 healthy and cancer donors, supporting ongoing research in NK cell–based therapies.
Read more:
immunitybio.com/immunitybio-…
NebraskaChase retweeted
BREAKING: The Left is calling on the UFC to DROP Sean Strickland for calling Bad Bunny a “f*ggot”
They seem to forget how Dana White operates:
“If you get your feelings hurt that bad don’t ask questions. I don’t tell any human what to say, no leashes”
NebraskaChase retweeted
𝗧𝗥𝗘𝗡𝗗𝗜𝗡𝗚: Fernando Mendoza was hilariously interviewed by Caleb Pressley 😭😭
This kid is an absolute gem.
NebraskaChase retweeted
Sorry about the confusion that came from “ medical scientific speak” in our press release on Friday! Folks read that as if patients failed to survive when the release meant the opposite!
The “Median 0verall survival “ is a scientific and standard endpoint used to measure survival and currently about 6 or so months is that mark sadly in these patients with brain tumors..meaning that 50percent of patients at this stage do not survive beyond this time frame of 6 months and longer. The fact that we have patients alive still at 12 months and that the “median has NOT YET been reached “ IS a positive and promising finding to date with our chemo free treatment in which patients have failed current standards of care.
Thanks for clarifying for all
Perhaps I should begin my “ Conversations” podcast soon so that I explain better rather than the statistical analysis speak!
$IBRX
I couldn't get that Press Release from Friday out of my head. So I asked Grok to explain it to me.
I was astonished! The explanation I received from Grok was unbelievable positive!!!
So I asked Grok to rewrite the Press Release in a way that people like me could understand it. Hope you enjoy this alternative PR! Boy, I really hope the company will rephrase Friday's press release!!
ImmunityBio Reports Encouraging Early Results in Recurrent Glioblastoma: Many Patients Alive Well Beyond Typical Survival
CULVER CITY, Calif. – January 23, 2026 – ImmunityBio, Inc. (NASDAQ: IBRX) today shared promising interim Phase 2 data from QUILT-3.078 in recurrent glioblastoma, one of the deadliest brain cancers.
Glioblastoma is extremely aggressive: after recurrence following standard treatment (surgery, radiation, temozolomide), most patients survive only 6–9 months. Five-year survival remains under 10%.
In this trial, as of January 22, 2026, 23 patients with recurrent Glioblastoma were enrolled — 19 remain alive. Among 14 with sufficient follow-up, survival is exceeding historical norms, including one patient at 12+ months ongoing from progression.
The therapy also reversed severe lymphopenia, boosting levels significantly and sustaining gains through 20 weeks.
“These durable signals in such a lethal disease offer real hope,” said Patrick Soon-Shiong, M.D., Founder and Executive Chairman. Larger randomized trials are advancing.
Updated results will be presented January 31, 2026, at the Stand Up to Cancer Glioblastoma Summit.